ExxonMobil Biomedical Sciences, Inc., Health and Environmental Sciences Division, Annandale, NJ, USA.
ExxonMobil Biomedical Sciences, Inc., Health and Environmental Sciences Division, Spring, TX, USA.
ALTEX. 2024 Jan 9;41(1):104-118. doi: 10.14573/altex.2201122. Epub 2023 Oct 12.
Difficult to test substances, including poorly soluble, mildly irritating, or UVCBs (unknown or variable composition complex reaction products or biological materials), producing weak or borderline in vivo results, face additional challenges in in vitro assays that often necessitate data integration in a weight of evidence (WOE) approach to inform skin sensitization potential. Here we present several case studies on difficult to test substances and highlight the utility of the toxicological priority index (ToxPi) as a data visualization tool to compare skin sensitization biological activity. The case study test substances represent two poorly soluble substances, tetrakis (2-ethylbutyl) orthosilicate and decyl palmitate, and two UVCB substances, alkylated anisole and hydrazinecarboximidamide, 2-[(2-hydroxyphenyl)methylene]-, reaction products with 2 undecanone. Data from key events within the skin sensitization adverse outcome pathway were gathered from publicly available sources or specifically generated. Incorporating the data for these case study test substances as well as data on chemicals of a known sensitization class (sensitizer, irritating non-sensitizer, and non-sensitizer) into ToxPi produced biological activity profiles which were grouped using unsupervised hierarchical clustering. Three of the case study test substances concluded to lack skin sensitization potential by traditional WOE produced biological activity profiles most consistent with non-sensitizing substances, whereas the prediction was less definitive for a substance considered positive by traditional WOE. Visualizing the data using bioactivity profiles can provide further support for WOE conclusions in certain circumstances but is unlikely to replace WOE as a stand-alone prediction due to limitations of the method including the impact of missing data points.
难以测试的物质,包括难溶性、轻度刺激性或 UVCB(未知或可变成分复杂反应产物或生物材料),其体内结果较弱或处于边缘状态,在体外检测中面临额外的挑战,这些检测通常需要采用证据权重(WOE)方法整合数据,以告知皮肤致敏潜力。本文介绍了几个关于难测试物质的案例研究,并强调了毒理学优先级指数(ToxPi)作为数据可视化工具的效用,用于比较皮肤致敏生物活性。案例研究测试物质代表两种难溶性物质,四(2-乙基己基)原硅酸酯和癸酸十六酯,以及两种 UVCB 物质,烷基化苯甲醚和肼基甲酰胺,2-[(2-羟基苯基)亚甲基]-,与 2-十一酮的反应产物。从公开来源或专门生成的来源收集了皮肤致敏不良结果途径内的关键事件数据。将这些案例研究测试物质的数据以及已知致敏类别(致敏剂、刺激性非致敏剂和非致敏剂)的化学品数据纳入 ToxPi 中,产生了生物活性谱,这些谱使用无监督层次聚类进行了分组。三个案例研究测试物质通过传统 WOE 得出的生物活性谱最符合非致敏物质,因此缺乏皮肤致敏潜力,而对于被传统 WOE 认为是阳性的物质,预测则不太确定。使用生物活性谱可视化数据可以在某些情况下为 WOE 结论提供进一步支持,但由于该方法的局限性,包括缺失数据点的影响,不太可能取代 WOE 作为独立预测方法。